CHILDHOOD PSYCHOSES:
RESULTS OF DRUG TREATMENT
WITH DOWN AND NON-DOWN
SUBJECTS
Renato COCCHI, a
neurologist and a medical psychologist.
(Italian translation) // Testo in italiano
Summary
After 3-94 months of individualized drug
therapy, the results of 44 psychotic Down children and 29 psychotic non-Down
children were compared. The Down group (PDG) comprised 28 M and 16 F; average
age at first consultation, 7;3 +/- 3;9 years; chromosomal diagnoses, 42 pure
trisomy 21, 1 mosaicism and 1 not known; DSM-III, R diagnosis, 40 early onset
and 4 late onset Pervasive Developmental Disorder.
The non-Down group (PnDG) comprised 16 M
and 13 F; average age at first consultation, 7;3 +/- 3;8 years; DSM-III, R
diagnosis, 19 early onset and 3 late onset Pervasive Developmental Disorder and
7 atypical Pervasive Developmental Disorders.
One Down child and 3 non-Down children
definitely came out of their psychoses and the results werå_ directly
correlated to the length of the drug therapy.
The high number of therapy interruptions,
especially with the Down children, may have various explanations, among wich
that of null or negative results does not seem the most prominent.
Key words: Childhood psychoses; Down children;
non-Down children; drug therapy; individualized regimen; results.
Autism
Down syndrome
Drug modulation of stress reactions
Mental retardation
Home Page // Pagina
iniziale
The possibility of comparing directly a
group of psychotic Down children (PDG) with a group of psychotic non-Down
children (PnDG), both tretaed by the same child psychiatrist, has already
allowed comparisons of notable interest in epidemiology and clinical features
(Cocchi, 1988), in the area of self-injurious behaviour (Cocchi & Bonaduce,
1988) and susceptibility towards upper tract respiratory diseases (Cocchi &
Bonaduce, 1988).
On first consultation the proposal of drug
treatment had been made in the case of every subject in the two groups,
although not necessarily accepted for various reasons (Cocchi, 1990c).
I therefore considered it of interest to
compare the results obtained with children whose parentó accepted the treatment
set along the guidelines adopted (Cocchi, 1990c).
As for fuller information, the two groups
will be described complete with all the psychotic children diagnosed as such on
first consultation.
Materials and method.
All the clinical records of psychotic Down
and non-Down subjects who consulted me between 1979 and the end of September
1990 were re-examined.
The records of all those over 15 years of
age (180 months to be precise) on first consultation were disregarded, despite
their being clearly autistic or suffering from a long lasting atypical childood
psychosis, having considered this age as the conventional limit of competence
as regards pediatrics anä child neuropsychiatry.
The reords selected were those in which the
assessment carried out during the first consultation revealed the following
symptoms, in differently composed combinations:
Other information asked and noted: sex, age
at firts consultation, chromosomal diagnose (for the Down subjects, and also
for the other children, if performed); age at which the parents first noted the
abnormal behaviour in their child.
Hallucinations, delusions, incoherence or
marked loosing of associations were never noted down, either at first visit or
during following consultations.
The diagnosis of early onset or late onset
or atypical Pervasive Developmental Disorder was made according to the DSM-III,
R (1987).
Results
According to the diagnoses made during first
consultation, 2 groups of children records were assembled.
1. Psychotic Down children group (PDG).
|
Nr. of Ss |
44 Ss = 100.00 %. |
|
Sex: |
M = 28 e F = 16 |
|
|
M/F ratio = 175/100 |
|
Chromosomal anomalies: |
|
|
Standard trisomy 21 |
42 Ss = 95.45 % |
|
Translocations |
0 " = 0.00 % |
|
Mosaicisms |
1 " = 2.27 % |
|
Only clinical diagnose |
1 " = 2.27 % |
|
|
|
|
Average age at 1st consult (years) |
7;3 +/- 3;9 |
|
|
|
|
Diagnosis according to DSM-III, R |
|
|
Early onset PDD |
40 Ss = 90.91 % |
|
Late onset PDD |
4 " = 9.09 % |
Table 1: Length of drug therapy in the PDG.
|
Subgroup |
Nr. of Ss and % |
|
0. Non started |
8 Ss = 18.18% |
|
1. from 3 to 6 months |
3 " = 6.82% |
|
2. from 7 to 12 months |
5 " = 11.36% |
|
3. from 13 to 24 months |
10 " = 22.73% |
|
4. from 25 to 36 months |
8 " = 18.18% |
|
5. from 37 to 60 months |
6 " = 13.64% |
|
6. from 61 to 84 months |
4 " = 9.09% |
|
Totals |
44 Ss = 100.0 % |
Table 2: results; keys: (-) worsening; (=) null;
(+) slight improvement; (++) marked improvement; (+++) very marked improvement;
(++++) normalized behaviour.
|
Order nr. |
Isolat. |
Linguage |
Stereotip. |
Sameness |
Mood |
Self-aggr. |
Soc. bhv. |
Learn. bhv. |
|
Subgr.. 1 |
|
|||||||
|
182 |
= |
+ |
+ |
|
= |
+ |
= |
= (*) |
|
353 |
+ |
= |
+ |
|
+ |
++ |
+ |
+ (*) |
|
455 |
= |
+ |
= |
|
+ |
++++ |
+ |
= |
|
Subgr. 2 |
|
|||||||
|
32 |
= |
= |
- |
+ |
+ |
|
+ |
= (*) |
|
34 |
+ |
++ |
++ |
+ |
+ |
|
+ |
= (*) |
|
316 |
+ |
= |
+ |
|
++ |
- |
+ |
(*) |
|
332 |
+ |
+++ |
= |
|
+ |
|
++ |
+ (*) |
|
430 |
+ |
++ |
++ |
++ |
++ |
+ |
++ |
++ |
|
Subgr. 3 |
|
|||||||
|
124 |
+ |
++ |
+ |
|
ì |
++ |
++ |
(*) |
|
173 |
+ |
+ |
+ |
|
- (#) |
|
+ |
= (*) |
|
186 |
+ |
+ |
++ |
|
+ |
++++ |
++ |
+ (*) |
|
289 |
+ |
+ |
+ |
|
= |
= |
++ |
= (*) |
|
325 |
+ |
+ |
+ |
|
+ |
+++ |
++ |
+ (*) |
|
330 |
= |
= |
- |
|
+ |
- |
= |
+ (*) |
|
333 |
+ |
= |
= |
|
- |
- |
+ |
= (*) |
|
345 |
++ |
++ |
++ |
++ |
++ |
|
++ |
++ (*) |
|
400 |
+++ |
+++ |
+++ |
+++ |
++ |
|
+++ |
+++ |
|
433 |
++ |
+++ |
++ |
++ |
+++ |
++++ |
+++ |
++ |
|
Subgr. 4 |
|
|||||||
|
93 |
+++ |
++ |
+++ |
+++ |
++ |
++++ |
+++ |
++ (*) |
|
101 |
++ |
++ |
+ |
++++ |
++ |
|
+++ |
++ (*) |
|
120 |
+ |
= |
++ |
|
++ |
++ |
++ |
= (*) |
|
191 |
+ |
= |
+ |
+ |
+ |
++ |
++ |
= (*) |
|
225 |
+ |
= |
= |
|
+ |
++ |
+ |
+ (*) |
|
281 |
+++ |
++ |
++ |
|
++ |
|
++ |
+ (*) |
|
319 |
+ |
+ |
+ |
++ |
+ |
+++ |
+ |
= (*) |
|
372 |
+++ |
+++ |
+++ |
++++ |
++++ |
++++ |
+++ |
++ |
|
Subgr. 5 |
|
|||||||
|
49 |
+++ |
++ |
+++ |
|
+++ |
++++ |
+++ |
++ |
|
85 |
+ |
= |
++ |
+ |
++ |
|
++ |
= (*) |
|
242 |
++ |
+ |
++ |
++ |
++ |
|
++ |
= |
|
268 |
++ |
++ |
++ |
|
++ |
|
+++ |
+ |
|
284 |
+++ |
+ |
++ |
|
+++ |
++++ |
+++ |
++ |
|
308 |
+ |
= |
+ |
= |
+ |
+ |
+ |
= |
|
Subgr. 6 |
|
|||||||
|
7 |
+++ |
+++ |
+++ |
++++ |
++++ |
++++ |
+++ |
+++ |
|
206 |
++++ |
+++ |
++++ |
++++ |
+++ |
++++ |
+++ |
++ |
|
217 |
++ |
+++ |
++ |
|
+ |
- @ |
++ |
+ |
|
226 |
+++ |
+++ |
+++ |
|
+++ |
|
+++ |
++ |
(*) therapy interrupted
by the parents; (#) repeated episodes of manic excitment; (@) onset of severe
aggressiveness against the mother.
2. Psychotic non-Down group (PnDG).
|
Nr. of Ss |
29 Ss = 100.00 %. |
|
Sex: |
M = 16 e F = 13 |
|
|
M/F = 123/100 |
|
|
|
|
Average age at 1st consult (years) |
7;5 +/- 3;8 |
|
|
|
|
Diagnosis according to DSM-III, R |
|
|
Early onset PDD |
19 Ss = 65.52% |
|
Late onset PDD |
3 " = 10.34% |
|
Atypical PDD |
7 " = 24,14% |
Table 3: Lenght of drug therapy in the PNDG.
|
Subgroup |
No. of Ss and % |
|
0. Non taken |
5 Ss = 17.24% |
|
1. from 3 to 6 months |
4 " = 13.79% |
|
2. from 7 to 12 months |
3 " = 10.34% |
|
3. from 13 to 24 months |
6 " = 20.69% |
|
4. from 25 to 36 months |
2 " = 6.90% |
|
5. from 37 to 60 months |
5 " = 17.24% |
|
6. from 61 to 84 months |
4 " = 13.79% |
|
Totals |
29 Ss = 100.00 % |
Table 4: results; keys: (-) worsening; (=) null;
(+) slight improvement; (++) marked improvement; (+++) very marked improvement;
(++++) normalized behaviour.
|
Order nr. |
Isolat. |
Linguage |
Stereotip. |
Sameness |
Mood |
Self-aggr. |
Soc. bhv. |
Learn. bhv. |
|
Subgr.. 1 |
|
|||||||
|
F |
+ |
+ |
= |
+ |
+ |
= |
+ |
= |
|
M |
= |
= |
+ |
|
+ |
|
* |
= |
|
F |
+ |
++ |
+ |
|
+ |
++ |
+ |
= |
|
M |
= |
= |
+ |
= |
+ |
++ |
= |
= |
|
Sottogr.2 |
|
|||||||
|
M |
++ |
+ |
++ |
+ |
++ |
++ |
++ |
+ (*) |
|
M |
++ |
++ |
+ |
|
++ |
|
+ |
+ |
|
M |
++ |
= |
+ |
|
++ |
|
++ |
+ |
|
Sottogr. 3 |
|
|||||||
|
F (#) |
+ |
- |
- |
|
++ |
++++@ |
- |
(*) |
|
F |
++ |
= |
++ |
|
++ |
|
++ |
+ (*) |
|
M |
+ |
++ |
++ |
++ |
++ |
++ |
++ |
+ |
|
F |
++ |
= |
+ |
|
++ |
+++ |
++ |
+ (*) |
|
F |
++ |
++ |
+ |
+++ |
++ |
++++ |
++ |
= |
|
M |
++ |
+ |
++ |
+++ |
++ |
++++ |
++ |
+ |
|
Sottogr.4 |
|
|||||||
|
M |
+++ |
++++ |
+++ |
|
+++ |
|
+++ |
++ |
|
M |
++ |
+ |
++ |
++ |
++ |
|
++ |
+ |
|
Sottogr. 5 |
|
|||||||
|
M |
++ |
++ |
++ |
|
+ |
++ |
++ |
= (*) |
|
M |
+++ |
+++ |
++++ |
+++ |
+++ |
|
+++ |
= |
|
F |
+ |
+ |
++ |
|
++ |
+ |
+ |
= |
|
F |
++++ |
++++ |
++++ |
|
++++ |
|
++++ |
+++ |
|
F |
+ |
= |
= |
|
+ |
= |
+ |
+ (*) |
|
Sottogr. 6 |
|
|||||||
|
M |
++ |
= |
+++ |
|
+++ |
|
++ |
+ |
|
M |
++++ |
++++ |
+++ |
++++ |
++++ |
++++ |
++++ |
+++ |
|
F |
+++ |
+++ |
++++ |
++++ |
+++ |
|
++++ |
+++ |
|
F |
+++ |
+ |
+++ |
++++ |
++++ |
|
+++ |
+ |
(*) therapy interrupted; (#)
Rett's Syndrome (diagnosis made during the drug therapy); (@) it could be an
outcome of the motory regression.
Table 5: comparison of the lenghts of the
therapies
|
Field investigated |
PDG / Ss nr. |
% |
PnDG / Ss nr. |
% |
% Diff. |
|
0. Non started |
8 |
18.18 |
5 |
17.24 |
- 0.94 |
|
1. from 3 to 6 months |
3 |
8.28 |
4 |
13.79 |
+ 6.97 |
|
2. from 7 to 12 months |
5 |
11.36 |
3 |
10.34 |
- 1.02 |
|
3. from 13 to 24 months |
10 |
22.73 |
6 |
20.69 |
- 2.04 |
|
4. from 25 to 36 months |
8 |
18.18 |
2 |
6.90 |
-11.20 |
|
5. from 37 to 60 months |
6< |